4D Pharma shares have rocketed and I’m tempted to buy now

4D Pharma shares leapt last week and the momentum is continuing. Given its potential game-changer drugs, it’s a stock Andy Ross wants to add to his portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Investors who bought 4D Pharma (LSE: DDDD) shares have had a torrid 12 months. The share price of the biotechnology company has fallen by 30% over the last year. But they were down further until late last week (and this week so far) as the shares have recently leapt. It’s not immediately clear why the share price has risen so rapidly. What’s clear though is that 4D Pharma has a lot of potential and it’s for that reason that I’m tempted to buy the shares now.

Why I’m tempted to buy despite the risks 

Given that many investors won’t have heard of 4D Pharma, I’ll start by explaining what it does. It focuses on developing Live Biotherapeutic Products (LBPs), which are drugs derived from the human microbiome. It has developed its research to build MicroRx, which is a discovery platform that’s able to select those bacteria that have a therapeutic effect in specific diseases, including cancer.

The company has 10 main programmes in development. These include two drugs that have reached phase II clinical trials and are progressing relatively well through the drug testing process. It also has a research collaboration with MSD, a trade name of Merck to discover and develop Live Biotherapeutics for vaccines.

This close partnership with a major pharmaceuticals firm could open the door to further collaboration in future, I think, and Merck could even buy the therapies as they progress through the drugs approvals process. I believe this would be a good outcome for shareholders as it would raise cash and move 4D pharma towards being profitable. 

For now though, the company remains loss-making. Losses in 2020 were around £26m. Yet 4D Pharma has cash and cash deposits that cover about a year’s worth of research and development costs. In 2021 the biotech firm raised approximately $24.03m (£17.29m) in a private placement. It has also secured a credit facility for up to $30m with Oxford Finance SARL. That’s all good news, but despite this extra money, it could still need to once again call on investors for even more, which would have the effect of diluting any holdings. I feel that raising longer-term debt would usually be preferable from a shareholder perspective.

The bottom line

Given UK investors have no other share like 4D Pharma to buy, I think that if evidence builds around the value of the microbiome in healthcare, 4D Pharma’s shares should do well. Investing in the stock is clearly not about today’s fundamentals. The investment case is all about how 4D Pharma is a world leader in an exciting new area of healthcare innovation and about its future potential. 

Of course, it’s possible 4D Pharma shares could be worth nothing. It’s a speculative, high-risk company to invest in. There are no two ways about that to my mind. But most rewards involve calculated risks. So, I would put aside just a small part of my overall cash to add 4D Pharma shares to my portfolio, given their huge potential. If just some of what’s in the pipeline works as expected, it could be transformational. When — or if — the potential of the microbiome in healthcare is proven, the 4D Pharma share price could rise very quickly. It may be a roller coaster ride up to that point though, but it’s one I’m prepared for. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Andy Ross owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Electric cars charging in station
Investing Articles

Warren Buffett’s electric vehicle stock is smashing Tesla shares in 2025

Warren Buffett doesn’t get enough credit for owning this top-performing electric vehicle stock. In recent years, it’s been a brilliant…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Here’s how investors could target £5,174 a year in passive income from £5,000 in savings invested in this FTSE 100 gem…

This often overlooked FTSE 100 savings and investment giant has an ultra-high yield of 8.4%, which can generate enormous passive…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

A profitable penny stock with a well-covered 8% dividend yield! What’s the catch?

Mark Hartley dives into a rare penny stock that offers an 8% dividend yield, investigating whether it deserves a place…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

I slashed my monthly expenses by £300 to help me aim for a steady second income stream of £20k

This Fool's saving an extra £300 a month and investing it in a portfolio of dividends stocks to power his…

Read more »

Workers at Whiting refinery, US
Investing Articles

Come on Shell! Here’s why you could consider buying BP shares…

Following takeover speculation, James Beard’s put together a letter to Shell’s boss explaining why the energy giant could consider buying…

Read more »

National Grid engineers at a substation
Investing Articles

National Grid shares: a £1,000 investment 5 years ago is now worth…

National Grid shares are on the rise! Here’s how much money investors have made so far… and how much they…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

Vodafone shares: a £1,000 investment 5 years ago is now worth…

Vodafone shares have underwhelmed since 2020, but could the stock be on the verge of an explosive comeback? Here's what…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

Investing £1,000 in BT shares 5 years ago: here’s how much could have been made…

BT shares are on the rise as the company steers itself towards £2bn of free cash flow generation by March…

Read more »